Spero Therapeutics SPRO is gearing up to announce its quarterly earnings on Thursday, 2025-03-27. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel ...

The FDA's decision not to approve Spero Therapeutics' oral antibiotic tebipenem Hbr for adults with complicated urinary tract infections (cUTI) further increases the threat of antibiotic ...

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults with ...

The film by Akron native Pat Donovan looks at Spero's long career in Rock and Roll, starting with his days as a child working with his father, who was the producer of the syndicated music show ...